Authors/Disclosures
|
Timo Siepmann, MD
(Carl Gustav Carus Medical School)
|
The institution of Dr. Siepmann has received research support from German Federal Ministry of Health. Dr. Siepmann has received publishing royalties from a publication relating to health care. |
|
Ben M. Illigens, MD
(Beth Israel Deaconess Medical Center)
|
Dr. Illigens has received personal compensation for serving as an employee of Target Health. Dr. Illigens has received personal compensation for serving as an employee of BC Platforms. Dr. Illigens has received personal compensation for serving as an employee of NOVA Discovery. Dr. Illigens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RDP Pharma. Dr. Illigens has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Biomind Labs. Dr. Illigens has a non-compensated relationship as a Director with Partners for Patients that is relevant to AAN interests or activities. |
|
|
No disclosure on file |
|
Roy L. Freeman, MD
(Beth Israel Deaconess Hosp)
|
Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. |
|
Matthew Maas, MD, FAAN
(Northwestern University)
|
The institution of Dr. Maas has received research support from National Institutes of Health. |
|
Christopher H. Gibbons, MD, FAAN
(Beth Israel Deaconess Medical Center)
|
Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has stock in CND Life Sciences. Dr. Gibbons has received publishing royalties from a publication relating to health care. Dr. Gibbons has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Advisor with Department of Justice. |